iSTAT CSF Analysis for Earlier Leptomeningeal Metastasis Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for leptomeningeal metastasis (LM) are inadequate, leading to high false negative rates and ineffective treatment due to their reliance on invasive procedures like biopsies and microscopy, resulting in poor prognosis for patients with a mean survival of 8 to 10 weeks.

Innovation Solution

A diagnostic method using a point-of-care body fluid analyzer (iSTAT) to measure blood gas, blood chemistry, and hematological parameters in biological samples such as cerebrospinal fluid (CSF) for significant deviations like pH, PO2, lactate, glucose, sodium, and potassium levels to detect LM, combined with mass spectrometry for branched chain keto acids and amino acids, providing earlier and more accurate detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current diagnostic methods (biopsies and microscopy) are used to diagnose leptomeningeal metastasis, then a definitive diagnosis can be obtained, but the false negative rate is near 50% and the procedures are highly invasive

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidinvasiveness of procedure

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces mechanical biopsy procedures with a chemical/biochemical diagnostic system. The method uses a panel of biomarkers (including S100B, GFAP, and other proteins) measured in CSF to diagnose LM, substituting the mechanical tissue sampling approach with a biochemical analysis approach that is less invasive and has higher sensitivity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the diagnostic parameters from visual microscopy of tissue samples to quantitative measurement of multiple biomarker concentrations in CSF. By measuring the levels of specific proteins and comparing them against established thresholds, the system achieves higher diagnostic accuracy without invasive procedures

Inventive Principle:

Principle #35Parameter changes

2Loss of time

If current diagnostic protocols are used, then a diagnosis can be made, but the mean survival time is only 8 to 10 weeks due to delayed detection

Engineering Contradiction:

Improvetime to diagnosisVSAvoidsurvival outcome

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent enables preliminary detection of LM by measuring biomarkers in CSF before clinical symptoms become severe. The biomarker panel can detect LM at an earlier stage, allowing therapeutic intervention to begin sooner and potentially improving survival outcomes

Inventive Principle:

Principle #10Preliminary action

3Measurement precision

If invasive biopsy procedures are performed to obtain definitive diagnosis, then treatment can be targeted, but the false negative rate remains near 50%

Engineering Contradiction:

Improvediagnostic sensitivityVSAvoidcomplexity of diagnostic protocol

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent creates a universal diagnostic panel that can detect LM across multiple cancer types (melanoma, breast, lung, etc.) using the same biomarker measurement approach. This multi-functional system replaces the need for cancer-type-specific diagnostic procedures while maintaining high sensitivity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250244332A1Methods for diagnosing leptominingeal metastasis

Publication Date: 2025.07.31 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

AI summary

Disclosed are methods for the detection and treatment of leptomeningeal metastasis (LM).